Guggenheim analyst Debjit Chattopadhyay assumed coverage of Soleno Therapeutics with a Buy rating and $40 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLNO:
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Soleno Therapeutics price target raised to $44 from $39 at Oppenheimer
- Eight new option listings and one option delisting on November 8th
- Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Soleno Therapeutics reports Q3 EPS (95c), consensus (58c)